IFW

Sterne Kessler Goldstein Fox
ATTORNEYS AT LAW

Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Heidi L. Kraus
Edward W. Yee
Albert L. Ferro*
Donald R. Banowit
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaston*
Kimberly N. Reddick

Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhulier
Rae Lynn Prengaman
Jane Shershenovich*
Lawrence J. Carroll*
George S. Bardmesser
Daniel A. Klein*
Rodney G. Maze
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller*
Jon E. Wright*
LuAnne M. Yuricek*

John J. Figueroa
Ann E. Summerfield

Registered Patent Agents•
Karen R. Markowicz
Nancy J. Leith
Helene C. Carlson
Gaby L. Longsworth
Matthew J. Dowd
Aaron L. Schwartz
Mary B. Tung
Katrina Y. Pei
Bryan L. Skelton
Robert A. Schwartzman
Timothy A. Doyle
Jennifer R. Mahalingappa
Teresa A. Colella

Jeffrey S. Lundgren
Victoria S. Rutherford
Eric D. Hayes

Of Counsel
Kenneth C. Bass III
Evan R. Smith

*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to Federal Agencies

May 28, 2004

WRITER'S DIRECT NUMBER:
(202) 772-8615
INTERNET ADDRESS:
FRANKC@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1635

Re: U.S. Utility Patent Application
Application No. 09/964,667; Filed: September 28, 2001
For: **Transgenic Animals and Cell Lines for Screening Drugs Effective for the Treatment or Prevention of Alzheimer's Disease**
Inventors: de la Monte *et al.*
Our Ref: 0609.4370005/RWE/FRC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;

2. Reply to Notice to Comply with Sequence Listing Requirements;

3. Request to Open New Disk File;

4. Copies of the following documents that were filed on September 28, 2001:

   a. Paper Copy of Sequence Listing;
   b. Preliminary Amendment;
   c. SKGF Cover Letter (stating that the computer readable copy of the Sequence Listing and the paper copy are the same); and
   d. PTO date-stamped postcard; and

5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are

Application No.: 09/964,667

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- [X] 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- [ ] 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- [X] 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- [ ] 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- [ ] 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- [ ] 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- [ ] 7. Other:

Applicant Must Provide:

- [X] An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". (If the unidentified sequences are not provided on the CRF)
- [X] An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. (If the unidentified sequences are not provided in the paper copy)
- [X] A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). (If a new paper and/or CRF are required)

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support
Technical Assistance.....703-287-0200
To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
ATTORNEYS AT LAW
1100 NEW YORK AVENUE, N.W. • WASHINGTON, D.C. 20005-3934
PHONE: (202) 371-2600 • FACSIMILE: (202) 371-2540 • www.skgf.com

September 28, 2001

WRITER'S DIRECT NUMBER:
(202) 371-2643
INTERNET ADDRESS:
AFERRO@SKGF.COM

Commissioner for Patents
Washington, D.C. 20231

Box Patent Application

Re: U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)
(Divisional of Appl. No.: 09/380,203; § 371 Date: April 25, 2000)
Appl. No.: To Be Assigned; Filed: Herewith
For: **Transgenic Animals and Cell Lines for Screening Drugs Effective for the Treatment or Prevention of Alzheimer's Disease**
Inventors: DE LA MONTE *et al.*
Our Ref: 0609.4370005/ALF

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. PTO Utility Patent Application Transmittal (Form PTO/SB/05);

2. PTO Fee Transmittal (Form PTO/SB/17) (*in duplicate*);

3. A true copy of the latest inventor-signed U.S. Utility Patent Application No. 09/380,203; § 371 Date: April 25, 2000, entitled:

Transgenic Animals and Cell Lines for Screening Drugs Effective for the Treatment or Prevention of Alzheimer's Disease

and naming as inventors:

Suzanne DE LA MONTE; and

Jack R. WANDS

the application consisting of:

a. A specification containing:

i. 61 pages of description prior to the claims;

ii. 5 pages of claims (34 claims);

iii. a one (1) page abstract;

b. 13 sheets of drawings: (Figures 1, 2A-2F, 3A-3F, 4A-4H, 5A, 5B, 6A-6G, 7A-7C, 8A-8D, 9A, 9B, 10A, 10B, 11 and 12);

c. 9 pages of a paper copy of the sequence listing;

d. A computer readable copy of the sequence listing. In accordance with 37 C.F.R. § 1.82(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same;

e. A copy of the executed Declaration For Patent Application, as originally filed in U.S. Appl. No. 09/380,203; and

f. Application Data Sheet;

4. A Preliminary Amendment;

5. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3) (*in duplicate*);

6. Our check No. 32252 for $710.00 to cover the filing fee for patent application; and

7. Two (2) return postcards.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Albert L. Ferro
Attorney for Applicants
Registration No. 44,679

RWE/ALF/BKB:reid/awt
Enclosures

P:\USER\NATERRY\00099437-Sylo cover letter div
SKGF Rev. 8/1/00 mac

		Due Date:	None
Applicants:	De La Monte *et al.*	**Art Unit:**	*To Be Assigned*
		Examiner:	*To Be Assigned*
Application No.:	*To Be Assigned* (*Divisional of Appl. No.: 09/380,203; §371 Date: April 25, 2000*)	**Docket:**	0609.4370005
Filed:	Herewith	**Atty:**	ALF

For: **Transgenic Animals and Cell Lines for Screening Drugs Effective for the Treatment or Prevention of Alzheimer's Disease**

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. SKGF cover letter (*in duplicate*);
2. PTO Utility Patent Application Transmittal (Form PTO/SB/05) (*in duplicate*);
3. PTO Fee Transmittal (Form PTO/SB/17) (*in duplicate*);
4. A true copy of the latest inventor-signed U.S. Utility Patent Application No. 09/380,203; § 371 Date: April 25, 2000, entitled **Transgenic Animals and Cell Lines for Screening Drugs Effective for the Treatment or Prevention of Alzheimer's Disease** and naming as inventors: Suzanne De La Monte and Jack R. Wands, the application consisting of: A specification including sixty-one (61) pages of description prior to the claims; five (5) pages of claims (34 claims), a one page abstract, and thirteen (13) sheets of drawings (Figures 1, 2A-2F, 3A-3F, 4A-4H, 5A, 5B, 6A-6G, 7A-7C, 8A-8D, 9A, 9B, 10A, 10B, 11 and 12); 9 pages of a paper copy of the sequence listing; and a computer readable copy of the sequence listing. In accordance with 37 C.F.R. § 1.82(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same.
5. A copy of the Declaration For Patent Application as originally filed in U.S. Appl. No. 09/380,203;
6. Application Data Sheet;
7. Preliminary Amendment;
8. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3) (*in duplicate*);
9. Two (2) return postcards; and
10. Our Check No. 32252 in the amount of $710.00 to cover the filing fee for patent application.

Box: Patent Application

Please Date Stamp And Return To Our Courier